Alzheimer's blood tests that received FDA clearance in 2025–2026 can detect amyloid and tau proteins—hallmarks of Alzheimer's pathology—in people who have cognitive symptoms. However, FDA clearance does not mean these tests diagnose Alzheimer's disease; instead, it means they reliably detect the brain plaques and tangles associated with Alzheimer's, but a doctor must still use cognitive testing and clinical judgment to reach a diagnosis. The availability of these tests represents a significant shift: blood tests now replace the need for invasive PET imaging or spinal fluid taps in many cases, making early screening more accessible. Understanding what clearance means—and what it doesn't—is essential for anyone considering testing.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- FDA Alzheimer's Blood Test Press Release — Use this primary source to verify the official announcement.
- FDA Clearance Summary — Use this primary source to review the underlying data.
Table of Contents
- The Two FDA-Cleared Blood Tests
- Accuracy—With a Critical Caveat
- What FDA Clearance Actually Means
- Who Is Eligible and What Comes Next
- Alternatives and the Broader Testing Landscape
- Frequently Asked Questions
The Two FDA-Cleared Blood Tests
Two blood tests received FDA clearance for Alzheimer's detection between May and October 2025. Fujirebio's lumipulse G pTau217/β-Amyloid 1-42 plasma ratio test received FDA clearance on May 16, 2025, becoming the first blood test cleared to aid Alzheimer's diagnosis in adults age 55 and older with cognitive symptoms. In October 2025, Roche's Elecsys pTau181 plasma test received FDA clearance—notably, the first blood test cleared for primary-care use, allowing general practitioners to order it without specialty referral.
Both tests measure phosphorylated tau or tau/amyloid ratios in blood plasma. These proteins accumulate in the Alzheimer's brain and can now be detected without surgery or anesthesia. The shift from imaging to blood tests has made screening faster and more accessible.
Accuracy—With a Critical Caveat
In clinical trials, Fujirebio's Lumipulse showed strong accuracy: 91% of positive results were confirmed by amyloid PET imaging or cerebrospinal fluid analysis, and 97% of negative results correctly ruled out amyloid pathology. Roche's Elecsys pTau181 was designed as a "negative-predictive" tool, meaning it is most useful for ruling out Alzheimer's pathology—97.9% of negative results correctly excluded amyloid or tau pathology in low-risk populations.
However, in early 2026, Fujirebio placed Lumipulse on manufacturing quality hold after independent data presented at the 18th Clinical Trials on Alzheimer's Disease conference showed false-positive rates as high as 40% in some patient populations. This means some blood samples flagged as positive may not show amyloid pathology on imaging. If your doctor recommends Lumipulse, confirm current availability and discuss limitations before testing.
What FDA Clearance Actually Means
FDA clearance for these tests means they are validated to detect amyloid or tau pathology, but it explicitly does NOT mean they diagnose Alzheimer's disease. Both tests are aids to detect neuropathology, not standalone diagnostic tools: a positive result shows your brain has hallmark plaques and tangles, but Alzheimer's requires additional factors—memory loss affecting daily function, difficulty with familiar tasks, and ruling out other causes like stroke, vitamin deficiency, or depression. Think of it this way: a blood test detecting amyloid is like a smoke detector.
It alerts you to smoke, but smoke can come from a fire, a toaster, or a candle. A doctor must investigate the source. Roughly 30% of cognitively normal older adults have amyloid in their brains but no symptoms—so a positive blood test does not automatically mean dementia will develop.
Who Is Eligible and What Comes Next
Both FDA-cleared tests are indicated for adults age 55 and older who have cognitive impairment or express concern about cognitive decline—not for asymptomatic screening of healthy people. Your doctor will typically order the test if you report memory loss, confusion, or difficulty with familiar tasks.
If your test is positive, your doctor will likely recommend: cognitive testing (such as the Montreal Cognitive Assessment), brain imaging (MRI to rule out stroke), blood work to exclude vitamin deficiencies or thyroid problems, and possibly referral to a neurologist or geriatrician. If negative, it reassures you that Alzheimer's pathology is not present—especially valuable if you have a family history or worry about dementia risk.
Alternatives and the Broader Testing Landscape
As of spring 2026, CLIA-certified labs including Quest Diagnostics and Labcorp offer additional plasma phosphorylated tau panels via laboratory-developed tests (LDTs). These are not FDA-cleared but meet laboratory certification standards; they may provide faster results or lower costs than FDA-cleared tests in some regions. Ask your doctor whether they recommend an FDA-cleared test or a certified lab-developed panel, and confirm your insurance coverage, as availability and reimbursement vary widely.
Frequently Asked Questions
If my blood test is negative, does that mean I don't have Alzheimer's?
A negative result from an FDA-cleared test makes Alzheimer's-related amyloid or tau pathology very unlikely (97–98% accuracy). However, it does not rule out other causes of cognitive decline, such as vascular dementia, Lewy body disease, or frontotemporal dementia. Cognitive symptoms still warrant evaluation by a doctor.
Can I get tested if I'm not showing symptoms yet?
No. Both FDA-cleared tests are indicated only for people age 55 and older with cognitive impairment or concern about decline. They are not recommended for asymptomatic screening. However, research studies are exploring whether blood tests could eventually identify at-risk individuals before symptoms appear.
Why was Lumipulse placed on hold?
Fujirebio placed Lumipulse on quality hold in 2026 after independent research showed unexpectedly high false-positive rates (up to 40%) in some cohorts. This does not mean the test is inherently flawed, but rather that quality control or interpretation standards may need refinement. Consult your doctor about current availability and whether an alternative test is advisable.
How much do these tests cost?
Lumipulse and Elecsys typically cost $400–$1,500 depending on the lab and insurance. Many insurance plans cover them if ordered by a doctor for cognitive concerns, but coverage varies. Ask your lab or doctor's office for a cost estimate before testing.
